Ropes & Gray Boosts Biopharmaceutical Patent Litigation Practice with Addition of Filko Prugo, M.S., J.D.

Monday, February 5, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Feb. 5, 2018 /PRNewswire/ -- Global law firm Ropes & Gray today announced that Filko Prugo, M.S., J.D.,

has joined its New York office as partner and chair of the firm's life sciences intellectual property litigation practice. Mr. Prugo, renowned for his understanding of life sciences patent issues, is a first-chair litigator
and a nationally recognized practitioner of Hatch-Waxman Act and Biologics Price Competition and Innovation Act (BPCIA) matters.

Ropes & Gray's IP practices are thriving, and Mr. Prugo's arrival follows the recent addition of Scott McKeown, who joined Ropes & Gray in August 2017 as a partner in the firm's Washington, D.C. office and chair of the firm's Patent Trial and Appeal Board (PTAB) practice.

The addition of Mr. Prugo will especially benefit Ropes & Gray's clients in the pharmaceutical and biologics space. He brings a solid foundation in chemistry and biotechnology, along with 20 years of experience representing the world's leading biopharmaceutical companies. Mr. Prugo has been extensively involved in all aspects of contested patent matters, and is among a handful of attorneys who have argued before all three patent venues of importance to life sciences clients in the United States: federal district courts for Abbreviated New Drug Application (ANDA) litigation, the Patent Trial and Appeal Board (PTAB), and the Court of Appeals for the Federal Circuit.

Mr. Prugo has led more than 20 litigation trial teams in his career. He has successfully tried and won cases in the U.S. District Court for the District of Delaware on behalf of Novartis and Sanofi Genzyme. He also argued a pair of IPR proceedings on behalf of Sanofi Genzyme—the first relating to marketed biologics—and he recently helped obtain favorable settlements on behalf of AstraZeneca in Hatch-Waxman litigations and IPRs involving a hormone-dependent breast cancer treatment. He joins Ropes & Gray from O'Melveny & Myers LLP, where he was partner and co-founder of the firm's Hatch-Waxman and BPCIA practice.

"Filko's significant ANDA litigation experience, winning litigation record and deep understanding of both chemistry and biotechnology will benefit our life sciences clients immediately," said Andrew Thomases, head of Ropes & Gray's IP litigation practice. "We are excited to welcome him to the firm."

"Our focus has been to grow Ropes & Gray in New York and to provide the highest-quality counsel to our clients," said Eva Carman, co-managing partner of Ropes & Gray's New York office. "Filko's energy and experience are a perfect combination for the firm and to further our efforts here."

Mr. Prugo has been widely recognized for his excellence in patent litigation, including in The Legal 500 US, LMG Life Sciences and, most recently, in the 2017 edition of Who's Who Legal: Patents. He is also a frequent speaker on developments in patent law, specifically as they concern Hatch-Waxman and BPCIA litigation.

A registered patent attorney with the U.S. Patent and Trademark Office, Mr. Prugo received his J.D. from Osgoode Hall Law School in Toronto, Canada, an M.S. in biotechnology from Johns Hopkins University (2017), and a B.S. (with first-class honors) in chemistry from York University in Toronto. He is a member of the Pharma & Biotech Committee of the Intellectual Property Owners Association.

"When the opportunity to join Ropes & Gray in a leadership position presented itself, it seemed like a natural next step," Mr. Prugo said. "My extensive chemistry and biotech patent litigation experience nicely complements the firm's strong focus on the life sciences industry."

About Ropes & Gray

Ropes & Gray's intellectual property practice combines a sophisticated understanding of the latest legal developments with cutting-edge technical and scientific knowledge to offer an all-inclusive suite of IP services.

The firm's global IP work covers a wide range of industries, including life sciences, technology and media, retail and consumer, private equity and financial services, and health care and education. In the highly competitive world of intellectual property, Ropes & Gray's IP attorneys are regularly recognized for their legal acumen by Chambers, The Legal 500, Managing Intellectual Property, Intellectual Asset Management and other national and global publications. The firm was also recognized by U.S. News & World Report as 2017 "Law Firm of the Year" for patent law.

Ropes & Gray is a preeminent global law firm with more than 1,200 lawyers and legal professionals serving clients in major centers of business, finance, technology and government. The firm has offices in New York, Boston, Washington, D.C., Chicago, San Francisco, Silicon Valley, London, Hong Kong, Shanghai, Tokyo and Seoul, and has consistently been recognized for its leading practices in many areas, including private equity, M&A, finance, investment management, hedge funds, real estate, tax, antitrust, life sciences, health care, intellectual property, litigation & enforcement, privacy & cybersecurity and business restructuring.  www.ropesgray.com

CONTACT:

Eric Goldman Senior Public Relations Specialist Ropes & Gray eric.goldman@ropesgray.com +1 212 596 9089

Cision View original content:http://www.prnewswire.com/news-releases/ropes--gray-boosts-biopharmaceutical-patent-litigation-practice-with-addition-of-filko-prugo-ms-jd-300593455.html

SOURCE Ropes & Gray



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store